Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Neisseria meningitidis Infections Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Neisseria meningitidis Infections Drug Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Neisseria meningitidis Infections Drug Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Type
    • 1.4.2 MGBBP-3
    • 1.4.3 NCL-195
    • 1.4.4 TP-10
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Neisseria meningitidis Infections Drug Market Size, Estimates and Forecasts
    • 2.1.1 Global Neisseria meningitidis Infections Drug Revenue 2015-2026
    • 2.1.2 Global Neisseria meningitidis Infections Drug Sales 2015-2026
  • 2.2 Global Neisseria meningitidis Infections Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Neisseria meningitidis Infections Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Neisseria meningitidis Infections Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Neisseria meningitidis Infections Drug Competitor Landscape by Players

  • 3.1 Neisseria meningitidis Infections Drug Sales by Manufacturers
    • 3.1.1 Neisseria meningitidis Infections Drug Sales by Manufacturers (2015-2020)
    • 3.1.2 Neisseria meningitidis Infections Drug Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Neisseria meningitidis Infections Drug Revenue by Manufacturers
    • 3.2.1 Neisseria meningitidis Infections Drug Revenue by Manufacturers (2015-2020)
    • 3.2.2 Neisseria meningitidis Infections Drug Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Neisseria meningitidis Infections Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Neisseria meningitidis Infections Drug Revenue in 2019
    • 3.2.5 Global Neisseria meningitidis Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Neisseria meningitidis Infections Drug Price by Manufacturers
  • 3.4 Neisseria meningitidis Infections Drug Manufacturing Base Distribution, Product Types
    • 3.4.1 Neisseria meningitidis Infections Drug Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Neisseria meningitidis Infections Drug Product Type
    • 3.4.3 Date of International Manufacturers Enter into Neisseria meningitidis Infections Drug Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Neisseria meningitidis Infections Drug Market Size by Type (2015-2020)
    • 4.1.1 Global Neisseria meningitidis Infections Drug Sales by Type (2015-2020)
    • 4.1.2 Global Neisseria meningitidis Infections Drug Revenue by Type (2015-2020)
    • 4.1.3 Neisseria meningitidis Infections Drug Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Neisseria meningitidis Infections Drug Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Neisseria meningitidis Infections Drug Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Neisseria meningitidis Infections Drug Revenue Forecast by Type (2021-2026)
    • 4.2.3 Neisseria meningitidis Infections Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Neisseria meningitidis Infections Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Neisseria meningitidis Infections Drug Market Size by Application (2015-2020)
    • 5.1.1 Global Neisseria meningitidis Infections Drug Sales by Application (2015-2020)
    • 5.1.2 Global Neisseria meningitidis Infections Drug Revenue by Application (2015-2020)
    • 5.1.3 Neisseria meningitidis Infections Drug Price by Application (2015-2020)
  • 5.2 Neisseria meningitidis Infections Drug Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Neisseria meningitidis Infections Drug Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Neisseria meningitidis Infections Drug Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Neisseria meningitidis Infections Drug Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Neisseria meningitidis Infections Drug by Country
    • 6.1.1 North America Neisseria meningitidis Infections Drug Sales by Country
    • 6.1.2 North America Neisseria meningitidis Infections Drug Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Neisseria meningitidis Infections Drug Market Facts & Figures by Type
  • 6.3 North America Neisseria meningitidis Infections Drug Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Neisseria meningitidis Infections Drug by Country
    • 7.1.1 Europe Neisseria meningitidis Infections Drug Sales by Country
    • 7.1.2 Europe Neisseria meningitidis Infections Drug Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Neisseria meningitidis Infections Drug Market Facts & Figures by Type
  • 7.3 Europe Neisseria meningitidis Infections Drug Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Neisseria meningitidis Infections Drug by Region
    • 8.1.1 Asia Pacific Neisseria meningitidis Infections Drug Sales by Region
    • 8.1.2 Asia Pacific Neisseria meningitidis Infections Drug Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Neisseria meningitidis Infections Drug Market Facts & Figures by Type
  • 8.3 Asia Pacific Neisseria meningitidis Infections Drug Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Neisseria meningitidis Infections Drug by Country
    • 9.1.1 Latin America Neisseria meningitidis Infections Drug Sales by Country
    • 9.1.2 Latin America Neisseria meningitidis Infections Drug Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Neisseria meningitidis Infections Drug Market Facts & Figures by Type
  • 9.3 Central & South America Neisseria meningitidis Infections Drug Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Neisseria meningitidis Infections Drug by Country
    • 10.1.1 Middle East and Africa Neisseria meningitidis Infections Drug Sales by Country
    • 10.1.2 Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Neisseria meningitidis Infections Drug Market Facts & Figures by Type
  • 10.3 Middle East and Africa Neisseria meningitidis Infections Drug Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Beijing Minhai Biotechnology Co Ltd
    • 11.1.1 Beijing Minhai Biotechnology Co Ltd Corporation Information
    • 11.1.2 Beijing Minhai Biotechnology Co Ltd Description and Business Overview
    • 11.1.3 Beijing Minhai Biotechnology Co Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.1.5 Beijing Minhai Biotechnology Co Ltd Related Developments
  • 11.2 Biological E Ltd
    • 11.2.1 Biological E Ltd Corporation Information
    • 11.2.2 Biological E Ltd Description and Business Overview
    • 11.2.3 Biological E Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Biological E Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.2.5 Biological E Ltd Related Developments
  • 11.3 China National Pharmaceutical Group Corp
    • 11.3.1 China National Pharmaceutical Group Corp Corporation Information
    • 11.3.2 China National Pharmaceutical Group Corp Description and Business Overview
    • 11.3.3 China National Pharmaceutical Group Corp Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Products Offered
    • 11.3.5 China National Pharmaceutical Group Corp Related Developments
  • 11.4 GlaxoSmithKline Plc
    • 11.4.1 GlaxoSmithKline Plc Corporation Information
    • 11.4.2 GlaxoSmithKline Plc Description and Business Overview
    • 11.4.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Products Offered
    • 11.4.5 GlaxoSmithKline Plc Related Developments
  • 11.5 Griffith University
    • 11.5.1 Griffith University Corporation Information
    • 11.5.2 Griffith University Description and Business Overview
    • 11.5.3 Griffith University Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Griffith University Neisseria meningitidis Infections Drug Products Offered
    • 11.5.5 Griffith University Related Developments
  • 11.6 ImmunoBiology Ltd
    • 11.6.1 ImmunoBiology Ltd Corporation Information
    • 11.6.2 ImmunoBiology Ltd Description and Business Overview
    • 11.6.3 ImmunoBiology Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.6.5 ImmunoBiology Ltd Related Developments
  • 11.7 JN-International Medical Corp
    • 11.7.1 JN-International Medical Corp Corporation Information
    • 11.7.2 JN-International Medical Corp Description and Business Overview
    • 11.7.3 JN-International Medical Corp Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Products Offered
    • 11.7.5 JN-International Medical Corp Related Developments
  • 11.8 MGB Biopharma Ltd
    • 11.8.1 MGB Biopharma Ltd Corporation Information
    • 11.8.2 MGB Biopharma Ltd Description and Business Overview
    • 11.8.3 MGB Biopharma Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.8.5 MGB Biopharma Ltd Related Developments
  • 11.9 Panacea Biotec Ltd
    • 11.9.1 Panacea Biotec Ltd Corporation Information
    • 11.9.2 Panacea Biotec Ltd Description and Business Overview
    • 11.9.3 Panacea Biotec Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.9.5 Panacea Biotec Ltd Related Developments
  • 11.10 Pfizer Inc
    • 11.10.1 Pfizer Inc Corporation Information
    • 11.10.2 Pfizer Inc Description and Business Overview
    • 11.10.3 Pfizer Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Pfizer Inc Neisseria meningitidis Infections Drug Products Offered
    • 11.10.5 Pfizer Inc Related Developments
  • 11.1 Beijing Minhai Biotechnology Co Ltd
    • 11.1.1 Beijing Minhai Biotechnology Co Ltd Corporation Information
    • 11.1.2 Beijing Minhai Biotechnology Co Ltd Description and Business Overview
    • 11.1.3 Beijing Minhai Biotechnology Co Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Products Offered
    • 11.1.5 Beijing Minhai Biotechnology Co Ltd Related Developments
  • 11.12 Serum Institute of India Ltd
    • 11.12.1 Serum Institute of India Ltd Corporation Information
    • 11.12.2 Serum Institute of India Ltd Description and Business Overview
    • 11.12.3 Serum Institute of India Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Serum Institute of India Ltd Products Offered
    • 11.12.5 Serum Institute of India Ltd Related Developments
  • 11.13 Wellstat Vaccines LLC
    • 11.13.1 Wellstat Vaccines LLC Corporation Information
    • 11.13.2 Wellstat Vaccines LLC Description and Business Overview
    • 11.13.3 Wellstat Vaccines LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Wellstat Vaccines LLC Products Offered
    • 11.13.5 Wellstat Vaccines LLC Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Neisseria meningitidis Infections Drug Market Estimates and Projections by Region
    • 12.1.1 Global Neisseria meningitidis Infections Drug Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Neisseria meningitidis Infections Drug Revenue Forecast by Regions 2021-2026
  • 12.2 North America Neisseria meningitidis Infections Drug Market Size Forecast (2021-2026)
    • 12.2.1 North America: Neisseria meningitidis Infections Drug Sales Forecast (2021-2026)
    • 12.2.2 North America: Neisseria meningitidis Infections Drug Revenue Forecast (2021-2026)
    • 12.2.3 North America: Neisseria meningitidis Infections Drug Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Neisseria meningitidis Infections Drug Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Neisseria meningitidis Infections Drug Sales Forecast (2021-2026)
    • 12.3.2 Europe: Neisseria meningitidis Infections Drug Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Neisseria meningitidis Infections Drug Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Neisseria meningitidis Infections Drug Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Neisseria meningitidis Infections Drug Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Neisseria meningitidis Infections Drug Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Neisseria meningitidis Infections Drug Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Neisseria meningitidis Infections Drug Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Neisseria meningitidis Infections Drug Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Neisseria meningitidis Infections Drug Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Neisseria meningitidis Infections Drug Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Neisseria meningitidis Infections Drug Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Neisseria meningitidis Infections Drug Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Neisseria meningitidis Infections Drug Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Neisseria meningitidis Infections Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Neisseria meningitidis Infections Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Neisseria meningitidis Infections Drug Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Neisseria meningitidis Infections Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neisseria meningitidis Infections Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Neisseria meningitidis Infections Drug market is segmented into
    MGBBP-3
    NCL-195
    TP-10
    Others

    Segment by Application, the Neisseria meningitidis Infections Drug market is segmented into
    Hospital
    Clinic
    Others

    Regional and Country-level Analysis
    The Neisseria meningitidis Infections Drug market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Neisseria meningitidis Infections Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Neisseria meningitidis Infections Drug Market Share Analysis
    Neisseria meningitidis Infections Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neisseria meningitidis Infections Drug business, the date to enter into the Neisseria meningitidis Infections Drug market, Neisseria meningitidis Infections Drug product introduction, recent developments, etc.

    The major vendors covered:
    Beijing Minhai Biotechnology Co Ltd
    Biological E Ltd
    China National Pharmaceutical Group Corp
    GlaxoSmithKline Plc
    Griffith University
    ImmunoBiology Ltd
    JN-International Medical Corp
    MGB Biopharma Ltd
    Panacea Biotec Ltd
    Pfizer Inc
    Sanofi Pasteur SA
    Serum Institute of India Ltd
    Wellstat Vaccines LLC

    Buy now